CAMBRIDGE, Mass., April 9 -- CompuCyte Corp. has concluded a restructuring of its operations, allowing it to refocus on its successful line of laser scanning cytometers (LSCs). CompuCyte also reported the completion of a round of private financing, providing the company with $4 million in working capital. Additionally, the company is completing development of the next generation of its LSC product line. The new instrument, a fully automated laser scanning cytometer, uses an inverted measurement platform and database software that is well suited for arrays of high-content cell specimens such as multiwell microtiter plates and tissue arrays. CompuCyte said realigning the business to capitalize on the unique benefits of its proprietary technologies is its initial step to expand its position in the high-end biopharmaceutical research market.